Russell J. Schilder

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 994 citations · Full text

Medicine, Oncology, Immunotherapy +14

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma

Thomas E. Witzig, Christine A. White, Gregory A. Wiseman et al. · Journal of Clinical Oncology · 1999 · 539 citations

Medicine, Hematology, Oncology +17

Focus on epithelial ovarian cancer

Robert F. Ozols, Michael A. Bookman, Denise C. Connolly et al. · Cancer Cell · 2004 · 298 citations · Full text

Medicine, Gynecology, Oncology +12

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani et al. · Blood · 2002 · 266 citations · Full text

Medicine, Immunology, Oncology +14